Exosomes in HIV infection

Jing Chen, Chuanyun Li, Rong Li, Huan Chen, Dexi Chen, and Weihua Li

INTRODUCTION

Acquired immunodeficiency syndrome (AIDS) is a primary global public health concern. The human immunodeficiency virus (HIV) is the pathogen of AIDS. Since AIDS has been identified, >37 million people worldwide have been infected [1]. Presently, highly active antiretroviral therapy (HAART) inhibits HIV replication and improves patient prognosis, turning AIDS into a chronic viral infectious disease [2]. However, due to the existence of HIV reservoir [3], HAART cannot eliminate the virus completely from the body [4]. After the treatment is stopped, the latent HIV can be reactivated [5]. Hence, AIDS patients cannot yet be cured. Therefore, understanding the factors that affect HIV disease progression and cause cytopathic effects is the key to eliminating HIV completely and curing AIDS permanently.

Several studies have demonstrated that the generation process of exosomes has considerable overlap with viral assembly and outflow pathways of HIV, suggesting that exosomes play a significant role in the HIV infection process. Typically, the exosomes can transport viruses from the infected cells to uninfected cells, regulating the host’s immune response to virus infection [6,7]. Moreover, exosomes can transmit disease-causing information, which affects the outcome of virus infections [8*]. HIV is the first RNA virus used for exosome research. Although some breakthroughs have been made with respect to the correlation between HIV and exosomes, the specific biological function has not yet been clarified. This study reviews the correlation between exosomes and HIV and the application of exosomes in HIV infection.

*Beijing Institute of Hepatology and ^Department of General Surgery, Beijing Youan Hospital, Capital Medical University, Beijing, China
Correspondence to Weihua Li, Beijing Institute of Hepatology, Beijing Youan Hospital, 8 Xitoutiao, Youannya, Fengtai District, Beijing 100069, China. E-mail: liweihua@183.com

Curr Opin HIV AIDS 2021, 16:262–270
DOI:10.1097/COH.0000000000000694

This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
KEY POINTS

- As a carrier of material exchange and information transmission, exosomes play an important role in the progression of HIV disease.
- Exosomes have dual effects on HIV infection, which can inhibit HIV infection and promote HIV infection.
- Exosomes can activate the resting HIV-infected CD4+ T lymphocytes, thereby activating the latent HIV reservoir.
- Exosomes play an important role in HIV-associated chronic inflammation.
- Biological information carried by exosomes can be used as markers in the process of HIV infection, which plays an important role in the diagnosis and treatment of HIV.

SOURCES AND BIOLOGICAL CHARACTERISTICS OF EXOSOMES

Exosomes are small extracellular vesicles derived from various cell types under physiological or pathological conditions. Polymorphic vesicles or exosomes were first discovered in sheep reticulocytes by Johnstone et al. [9]. Originally, exosomes were thought of as a way for cells to get rid of metabolic waste. Later, studies found that exosomes secreted by B lymphocytes contain histocompatibility class II antigen complexes, which can induce the immune response of T lymphocytes [10]. Therefore, exosomes gradually attracted people’s attention. Exosomes have a lipid bilayer structure with a diameter of 30–150 nm and a density of about 1.13–1.19 g/ml [11]. In the presence of sufficient water, exosomes are round when viewed under a low-temperature microscope [12,13]. At present, it has been found that exosomes have morphological diversity in body fluids, and some studies have classified exosomes derived from human mast cells 1 (HMC-1) into nine categories according to their different morphologies. Previous studies have shown that exosomes come from a wide range of sources and can be released into the microenvironment by a variety of different cells [14]. They are found in a variety of biological fluids, including blood [15], urine [16], breast milk [17], and semen [18]. Exosomes contain abundant macromolecular substances, such as proteins, nucleic acids, and lipids [19–21], and their surfaces contain specific protein markers, such as CD9, CD63, and CD81 [22], which can be used as specific markers for the identification of exosomes. Exosomes serve as the carriers of cell signaling molecules and mediate cell-to-cell transmission, promote the transport of proteins and nucleic acids and effectuate disease development [23]. In addition to participating in multiple processes such as intercellular signal transduction, extracellular mechanism generation, and tumor interstitial communication [24], exosomes also play an important role in viral infection. For example, exosomes can both deliver antiviral agents between different cells [25] and target viral antigens to allow the virus to evade host immunity [24,26].

FORMATIONS OF EXOSOMES AND HIV PARTICLES

The features of HIV particles overlap with exosomes. Both are composed of a lipid bilayer membrane and can carry genetic material. Also, the density of HIV (1.16–1.18 g/ml [27]) and diameter (100 nm) are similar to those of exosomes. However, these similarities render isolating exosomes from the HIV virus rather challenging.

Exosomes are a series of membranous nanovesicles and generated as follows. First, the cell membrane invaginates to form an endosome. Then, the endosomal membrane is dented, budding inwards to form multivesicular bodies (MVBs) containing intraluminal vesicles (ILVs). Finally, some MVBs fuse with lysosomes for degradation [28], whereas others whose membrane surface contains CD63 and lysosomal associated membrane protein 1 (LAMP1) mediate the fusion of MVBs with the cell membrane to release ILVs in the extracellular space. These vesicles then convert into exosomes [29]. The biogenesis of ILVs and MVBs is driven by two mechanisms: Endosomal Sorting Complex Required for Transport machinery (ESCRT-dependent) and ESCRT-independent. ESCRT consists of four protein complexes (ESCRT-0, -I, -II, and -III) and some associated proteins (Alix and VPS4) [30], each with varied functions. ESCRT-0 recognizes and aggregates ubiquitinated proteins on the endosomal membrane [31] and recruits ESCRT-I. ESCRT-I merges with ESCRT-II to promote endosomal membrane invagination and bring RNA and proteins into the newly formed vesicle. Subsequently, ESCRT-II recruits ESCRT-III to sever the connection between the endosomal membrane and the vesicle to separate the vesicle [32]. Moreover, the ESCRT-I-related protein, tumor susceptibility gene 101 protein (TSG101), and ESCRT-III-related proteins, Alix, and CHMP4, play critical roles in developing exosomes. Some studies have shown that exosomes decrease when the levels of these proteins are low [33,34]. In addition, ILVs and MVBs can be generated even when the cell is depleted of the four ESCRT protein complexes [35], indicating that the biogenesis of ILVs and MVBs can be driven in an ESCRT-independent manner where four transmembrane proteins and some lipid molecules, such as...
as ceramide, are involved [19]. Current studies have demonstrated that Ral GTPase regulates the biogenesis of MVBs and the secretion of exosomes [36]. This finding is valuable to the study of exosomes.

The formation of HIV particles has many features overlapping those of exosomes. The budding of HIV requires ESCRT, as well as TSG101 and Alix [37]. HIV is constituted of three structural proteins: Gag, Pol, and Env. Among these, Gag is the only necessary protein for HIV formation. It assembles at the plasma membrane to generate the virus particles [38], interacts with TSG101 protein, and recruits ESCRT-I to the plasma membrane. Then, ESCRT-I recruits ESCRT-II to the plasma membrane. TSG101 protein merges with AIP1 protein and interacts with CHMP4 in ESCRT-III. ESCRT-III binds to the plasma membrane to form a complex cellular protein [39] that nourishes HIV budding. ESCRT-III with the plasma membrane forms vesicles to encase the virus particles. Subsequently, the vesicles separate after plasma membrane fission [40,41] and fuse with the cell membrane to release the virus. The cellular protein Vps4 is crucial for this process. It is recruited to the plasma membrane to facilitate the release of ESCRT components from the vesicles after virus budding and effectuate the recycling of ESCRT components [42]. The similarity between the formation process of exosomes and the budding process of HIV complicates the research on exosomes. Figure 1 describes the formation of exosomes and the budding process of HIV.

**ROLE OF EXOSOMES IN HIV DISEASE PROGRESSION**

Exosomes are crucial to the development of HIV. The pathogenesis of HIV is complex, and the molecular substances in the virus are important to the disease progression. Being the carriers of material exchange, exosomes play a key role in cell communication [43]. Studies have shown that exosomes can transfer the substances from the HIV virus among cells, which affects the occurrence and development of the disease. In the following sections, the present paper will introduce the impact of exosomes on HIV disease progression and the application of exosomes in HIV treatment.

**INHIBITION OF EXOSOMES IN HIV INFECTION**

The exosomes released by T cells contain a large number of CD4+ molecules, whose exosomes compete with host cells to bind to the HIV envelope protein, inhibiting the HIV infection of target cells [44]. The exosomes are crucial to cell-to-cell communication as they can mediate intercellular communication by delivering functional factors to recipient cells [45]. Previous studies have shown that exosomes contain multiple antiviral factors that inhibit replication in HIV [46,47]. Human cytidine dehydrogenase APOBEC3G (A3G) is a part of the defense system against HIV. Exosomes carrying A3G reduce HIV replication [48]. In addition, Human intestinal epithelial cells (IECs) and human brain microvascular endothelial cells (HBMECs) are activated by TLR3 and release exosomes containing anti-HIV viral factors, including several vital interferon-induced genes (ISG15, ISG56, and Mx2) and anti-HIV miRNA, that inhibit HIV replication in macrophages [46,49]. Exosomes derived from body fluids can also inhibit HIV infection, while those in semen promote HIV transcriptional silencing by disrupting the NF-κB/Sp1/Tat pathway [50]. Moreover, human semen contains exosomes with anti-HIV activity. Exosomes from healthy human semen (SE) contain antiviral mRNA, which has been shown to inhibit HIV replication and weaken the infectivity of the progeny virus [51]. Madison et al. [52] demonstrated that SE in healthy individuals could prevent HIV spread from vaginal epithelial cells to target cells, and SE can inhibit reverse transcriptase activity of the offspring LP-BM5 murine HIV, and limit the transmission of murine HIV in the vagina. Similarly, exosomes in semen from the HIV infector also inhibit HIV replication in vitro, deliver antiretroviral drugs in the body [53**], and provide novel treatment approaches. Furthermore, exosomes in vaginal fluid and breast milk also inhibit HIV infection [25,54]. For example, exosomes in breast milk combine with dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN) to inhibit HIV infection and HIV spread in the dendritic cells derived from monocytes, indicating that the risk of mother-to-child transmission is reduced [25].

**PROMOTION BY EXOSOMES IN HIV INFECTION**

Some studies showed that exosomes promote HIV infection. HIV infects the cells by engaging CD4+ and coreceptors (CCR5 and/or CXCR4) at the cell surface and fusing the viral envelope to the cell membrane, promoting the internalization of the HIV particles. In addition, exosomes derived from monocytes and macrophages can transfer CCR5 and CXCR4 to the cells that lack coreceptors, thereby increasing the number of susceptible cells [55,56]. T cell immunoglobulins and T-cell Immunoglobulin and Mucin-domain containing proteins (TIMs) play a critical role in the immune system, invaded by enveloped viruses through TIMs [57,58]. HIV
contains a large amount of Phosphatidylserine (PtdSer), which can fuse with the PtdSer-receptor TIMs. Some studies have shown that exosomes contain TIMs, which can fuse with the PtdSer on the surface of HIV to facilitate its entry into T cells and macrophages. After the invasion, the virus is blocked by anti-TIM-4 [59]. Moreover, exosomes promote the maturation of DCs that upregulate the expression of costimulatory molecules on DCs. In this case, a large number of DC/T lymphocyte clusters are induced, and ultimately leads to higher levels of HIV metastasis to T lymphocytes [60].
Exosomes also carry some cytokines, such as interleukin (IL)-3, IL-4, IL-8, and IL-17 [61], which affect the virus’s life cycle and enhance HIV infection [62,63]. Some studies demonstrated that exosomes promote HIV infection by affecting HIV-derived proteins. The HIV accessory protein Nef is one of the most abundantly expressed viral proteins. The released exosomes contain HIV Nef protein [64], and the exosomes containing Nef protein increase the susceptibility of T cells to HIV infection [24,64]. In addition, exosomes containing Nef proteins have also been shown to accelerate T cell apoptosis, which may lead to depletion of CD4+ T cells in the AIDS mechanism [65]. Some studies have shown that the exosomes released by HIV-infected cells contain the viral envelope (Env) protein gp120, which promotes the virus to attach and fuse to the target cells and promote HIV infection in various indirect ways [66]. Figure 2 illustrates the dual function of exosomes in HIV infection.

**ACTIVATION OF EXOSOMES FOR HIV LATENT RESERVOIR**

HAART controls the HIV level of AIDS patients below the detection limit [67–69]. However, due to the existence of an HIV reservoir, HAART cannot eliminate the virus completely [70], and AIDS patients cannot yet be cured. The latent reservoirs are mainly generated when the viruses enter the activated CD4+ T lymphocytes and restore them to a resting state [71]. Supposedly, exosomes activate the resting HIV-infected CD4+ T lymphocytes via different mechanisms, which might cure AIDS. Exosomes from HIV-infected cells activate the resting CD4+ T lymphocytes via ADAM17 and TNF-α-dependent mechanisms [24,72]. Among these, Nef is the determinant factor for the exosomes to activate HIV [24,72]. It induces the exosomes to upregulate activated ADAM17 in target cells, following which mature tumor necrosis factor (TNF)-α is released [24,26,73] and the latent HIV is activated. HIV-coded Tat protein is an effective viral

**FIGURE 2.** The dual function of exosomes in HIV infection. (a) The inhibitory effect of exosomes on HIV infection. (b) The promotional effect of exosomes on HIV infection.
transcription transactivator. Tat protein is encapsulated in exosomes for targeted delivery to latently infected CD4+ T lymphocytes, which reactivate the virus. When combined with an HIV latency reversal agent (LRA), the expression of HIV mRNA increases by >30-fold [74]. In addition, the activation of T cells triggers the release of exosomes [75,76]. Also, exosomes derived from IL-2-activated CD4+ T cells can be preferentially internalized by their own cells and reactivate the resting CD4+ T cells of SIV-infected monkeys [77], which is a prerequisite for the potential application of exosomes in reactivating latent HIV.

**ROLE OF EXOSOMES IN HIV CHRONIC INFLAMMATION**

Chronic inflammation underlies pathological changes [78]. Accumulating evidence demonstrated that exosomes play a critical role in HIV-related chronic inflammation. The exosomes contain several proinflammatory factors derived from viruses or the host, affecting the development of the inflammation. Among these, the HIV-derived Nef protein is encapsulated in exosomes and transported to target cells, promoting the release of TNF-α [79]. In addition, the transactivated RNA (TAR RNA) in stem–loop structures is detected in the exosomes released by HIV-infected cells [80]. Some studies proved that TAR RNA could regulate the gene expression of proinflammatory cytokines, such as IL-6 and TNF-β, through the TLR-3 pathway [81]. Similarly, exosomes produced during HIV infection have also been shown to contain various inflammatory mediators derived from the host. Additionally, the exosomes of HIV-infected patients contain a variety of miRNAs that promote inflammation, such as miR-155, miR-223 [82], and miR-29a (which enhance the inflammatory response of macrophages) [83]. Moreover, HIF-1α facilitates IL-1β transcription [84], which directly promotes the development of inflammation. Accumulating evidence stated that exosomes from the plasma of HIV patients promote HIF-1α activity of lymphocytes and macrophages [85], which could be because exosomes deliver HIF-1α protein [86,87] or a long non-coding RNA to prevent the degradation of HIF-1α mRNA [88]. Chronic inflammation may occur in the central nervous system during HIV infection [89]. In this process, exosomes mediate the communication among cells, such as astrocytes, microglia, and other cells, which exert regulatory functions on neuroinflammation through a variety of mechanisms [90,91] and affect the inflammation of the nervous system by transferring proteins, nucleic acids, and other substances.

**SIGNIFICANCE OF BIOLOGICAL INFORMATION CARRIED BY EXOSOMES FOR HIV DISEASE**

The identification of biomarkers during antiretroviral therapy could lead to early identification of CD4+ cell recovery after treatment, which could be important for monitoring the treatment of HIV patients [92,93]. Some studies demonstrated that exosome-derived microRNA 192 (miR-192), IL-6, and soluble CD14 (SCD14) are related to the recovery of CD4+ cells at the beginning of antiretroviral therapy, and exosome-derived miR-144 is associated with the recovery of CD4+ cells after 96 weeks of antiretroviral therapy [94]. In addition, HIV exosomes are also shown to promote the spread of toxic factors, such as β-amyloid and prions. Furthermore, HIV exosomes are regulatory factors for neurodegenerative diseases [95]. Sun et al. [96] showed that

| Table 1. The role of some components of exosomes as markers in HIV disease |
| --- |
| Components | Functions | First author(s) | Year | References |
| --- | --- | --- | --- | --- |
| miR-192, IL-6, SCD14 | Related to the recovery of CD4+ cells at the beginning of antiretroviral therapy | Francisco Hernández-Walias | 2020 | [94**] |
| miR-144 | Related to the recovery of CD4+ cells at W96 of antiretroviral therapy | Francisco Hernández-Walias | 2020 | [94**] |
| HMGB1, NF-L, Aβ | Biomarkers for HIV cognitive impairment | Sun B | 2017 | [96] |
| miR-378, miR-630 | Monitor HIV status of infected mother and prevent mother-to-child transmission of HIV | Zahoor MA | 2020 | [97*] |
| miR-20a, miR-21 | Biomarkers of the risk of development of classic Hodgkin lymphoma in HIV-infected patients | Hernández-Walias FJ | 2020 | [98*] |
| miR-4516 | Biomarkers of related neurological diseases in HIV-infected patients | Asahchop EL | 2016 | [99] |

IL, interleukin; HMGB1, high mobility group protein B1; miR-192, microRNA 192; NFL, nerve filament light chain; SCD14, soluble CD14.
proteins associated with neuronal damage in plasma neuron-derived exosomes (NDE) of HIV-infected patients could be used as the biomarkers for HIV cognitive impairment. High mobility group protein B1 (HMGB1), nerve filament light chain (NF-L), and Aβ proteins are altered in plasma NDE after HIV infection and are crucial to cognitive impairment and treatment response after HIV infection. Table 1 summarizes the components in exosomes that sever as the biomarkers for HIV disease.

CONCLUSION
Exosomes play a critical role in AIDS progression and affect the occurrence, development, and outcome of HIV through multiple mechanisms and aspects (such as cell-to-cell transmission and interaction with HIV molecules and receptor cells). This review introduced the role of exosomes in HIV progression and described the application of exosomes in HIV disease. Due to the existence of an HIV reservoir, AIDS cannot be cured yet. However, if latent HIV can be eliminated completely, AIDS can be cured permanently. In recent years, some progress has been made in exosomes to activate the latent HIV; hence, the exosomes have become a hotspot in clinical studies for AIDS and are expected to have wide application prospects for AIDS treatment. Although several studies were carried out on the correlation between exosomes and HIV, a specific mechanism is not yet elucidated. Also, since exosomes are similar to virus particles in size, density, membrane composition, and biogenesis, the separation, purification, and identification of exosomes are challenging. Presently, iodixanol density gradient centrifugation [100] and size exclusion chromatography (SEC) [101,102] are two effective methods that obtain higher purity exosomes from virus-containing plasma, and the two approaches may complement each other [78]. However, all the current methods are incomplete due to their limitations and require improvement. In conclusion, a comprehensive study is required to elucidate the correlations between exosomes and HIV, and thus, eliminate HIV completely and cure AIDS permanently.

Acknowledgements
Authors’ contributions: C.J. and L.C.Y. conceived of the presented idea. L.R. and C.H. researched on the background of the study. L.W.H. and C.D.X. critically reviewed the manuscript. All authors contributed to and approved the final manuscript.

Financial support and sponsorship
The Natural Science Foundation of Beijing (7212172). Youan liver disease and AIDS Funding (YNKTS201801233). Fengtai District Health System Project (2018-63). Pilot project of public welfare development and reform of Beijing Municipal Medical Research Institutes (2019-6). Beijing Engineering Research Center for Precision Medicine and Transformation of Hepatitis and Liver Cancer.

Conflicts of interest
There are no conflicts of interest.

REFERENCES AND RECOMMENDED READING
Papers of particular interest, published within the annual period of review, have been highlighted as:

— of special interest
** of outstanding interest

1. Ortblad KF, Lozano R, Murray CJ. The burden of HIV: insights from the Global Burden of Disease Study. AIDS 2013; 27:2003–2013.
2. Lifes expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008; 372:293–299.
3. Chuu TW, Carmuh L, Finzi D, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997; 387:183–188.
4. Le T, Farrar J, Shikuma C. Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication. AIDS 2011; 25:871–872. author reply 872–3.
5. Bongiovanni M, Casana M, Tincali C, d’Arminio Monforte A. Treatment interruptions in HIV-infected subjects. J Antimicrob Chemother 2006; 58:502–505.
6. Li P, Kaslan M, Lee SH, et al. Progress in exosome isolation techniques. Theranostics 2011; 1:789–804.
7. Gallo A, Vella S, Mele M, et al. Global profiling of viral and cellular noncoding RNAs in Epstein–Barr virus-induced lymphoblastoid cell lines and released exosome cargos. Cancer Lett 2017; 388:334–343.
8. Shi Y, Du L, Li D, et al. Emerging role and therapeutic application of exosome in hepatitis virus infection and associated diseases. J Gastroenterol 2021; 56:339–349.

This review summarizes the new role and therapeutic applications of exosomes in hepatitis virus infection and related diseases.

9. Pan BT, Johnston RM. Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: selective externalization of the receptor. Cell 1983; 33:967–978.
10. Raposo G, Nijman HW, Stoorvogel W, et al. B lymphocytes secrete antigen-presenting vesicles. J Exp Med 1996; 183:1161–1172.
11. Merchant ML, Rood BM, Deegens JKJ, Klein JB. Isolation and characterization of urinary extracellular vesicles: implications for biomarker discovery. Nat Rev Urol 2017; 13:731–749.
12. Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol 2013; 200:373–383.
13. Bellingham SA, Guo BB, Coleman BM, Hill AF. Exosomes: vehicles for the transfer of toxic proteins associated with neurodegenerative diseases? Front Physiol 2012; 3:124. doi: 10.3389/fphys.2012.00124.
14. Lotvall J, Valadi H. Cell to cell signalling via exosomes through exRNA. Cell Adhes Migr 2007; 1:156–158.
15. Caby MP, Lankar D, Vincendeau-Scherrer C, et al. Exosomal-like vesicles are present in human blood plasma. Int Immunol 2005; 17:879–887.
16. Pisitkun T, Shen RF, Knepper MA. Identification and proteomic profiling of exosomes in human urine. Proc Natl Acad Sci USA 2004; 101:13368–13373.
17. Admyre C, Johansson SM, Gazi KR, et al. Exosomes with immune modulatory features are present in human breast milk. J Immunol 2007; 179:1989–1998.
18. Polakova A, Spilmann M, Dolkart T, et al. Structural heterogeneity and protein composition of exosome-like vesicles (prostasomes) in human semen. Prostate 2009; 69:159–167.
19. Trajkovic K, Hsu C, Chiantia S, et al. Ceramide triggers budding of exosome vesicles into multivesicular endosomes. Science 2008; 319:1244–1247.
20. Li X, Wang S, Zhu R, et al. Lung tumor exosomes induce a pro-inflammatory phenotype in mesenchymal stem cells via NFκB-TLR signaling pathway. J Hematol Oncol 2016; 9:42.
21. Colombo M, Raposo G, Thery C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol 2014; 30:255–289.
22. Lai RC, Tan SS, Yeo RW, et al. MSC secretes at least 3 EV types each with a unique permutation of membrane lipid, protein and RNA. J Extracell Vesicles 2016; 5:29828. doi: 10.3402/jev.v5.29828.
23. Kalluri R. The biology and function of exosomes in cancer. J Clin Invest 2016; 126:1208–1215.
24. Arenacchi C, Chiozzi C, Columbia-Cabases S, et al. Exosomes from human immunodeficiency virus type 1 (HIV-1)-infected cells license quiescent CD4+ T lymphocytes to replicate HIV-1 through a Nef- and ADAM17-dependent mechanism. Virol J 2014; 11:536.
25. Mack M, Klooschildt A, Bruhl M, et al. Transfer of the chemokine receptor CCR5 between cells by membrane-derived microvesicles: a mechanism for cellular human immunodeficiency virus 1 infection. Nat Med 2000; 6:769–775.
26. Moller-Tank S, Kondratowicz AS, Davve RA, et al. Role of the phosphatidylserine receptor TIM-1 in enveloped-virus entry. J Virol 2013; 87:8327–8341.
27. Jernely J, Wang Ji, Chan YK, et al. TIM-family proteins promote infection of multiple enveloped viruses through vitamin-associated phosphatidylserine. PLoS Pathogens 2013; 9:e1003232. doi: 10.1371/journal.ppat.1003232.
28. Sims BS, Parrow AL, Williams SD, et al. Role of TIM-4 in exosome-dependent entry of HIV-1 into human immune cells. Int J Nanomed 2017; 12:4823–4833.
29. Merciez SK, Dowaghy H, Botting RA, et al. The microvesicle component of HIV-1 inocula modulates dendritic cell infection and maturation and enhances adhesion to and activation of T lymphocytes. PLoS pathogens 2013; 9:e1003700. doi: 10.1371/journal.ppat.1003700.
30. Kadiu I, Narayanasamy P, Dash PK, et al. Biochemical and biogenic characterization of exosomes and microvesicles as facilitators of HIV-1 infection in macrophages. J Immunol 2012; 189:744–754.
31. Vals ML, Alu W, Rosati M, et al. Dual effect of interleukin 4 on HIV-1 expression: implications for viral phenotypic switch and disease progression. Proc Natl Acad Sci USA 1998; 95:8886–8891.
32. Pakianathan DR. Subversion of chemokine receptors by HIV: how can we exploit this? Expert Opin Investig Drugs 1997; 6:841–845.
33. Campbell TD, Khan M, Huang MB, et al. HIV-1 Nef protein is secreted into vesicles that can fuse with target cells and virions. Elife 2015; 8;1(Suppl 2). S2-14-19.
34. Lenassi M, Cagnesi G, Liao M, et al. HIV-Nef secreted in exosomes and exosome cargo promotes HIV-1 entry in CD4+ T cells. Traffic 2010; 11:110–122.
35. Arakelyan A, Fitzgerald W, Zicari S, et al. Extracellular vesicles carry Env and facilitate HIV infection of human lymphoid tissue. Scientific Rep 2017; 7:16915.
36. Pereleson AS, Essunger P, Cao Y, et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997; 387:198–201.
37. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997; 337:725–733.
38. Gillick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997; 337:734–739.
39. Siliciano RD, Kaaja R, Finzi D, et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 2003; 9:727–728.
40. Siliciano RF, Greene WC. HIV latency. Cold Spring Harbor Perspect Med 2011; 2). S2-14-19.
41. Wang Ji, Kaddour H, Winchester L, et al. Formulation and release of virus-like particles by HIV-1 matrix protein. AIDS 1999; 13:281–283.
42. Luiz J, Graviss EA, Bright NA. Endosome-lyosome fusion. Bioch Soc Trans 2010; 38:1413–1416.
43. Fujita Y, Kosaka N, Arai J, et al. Extracellular vesicles in lung microenvironment and pathogenesis. Trends Mol Med 2015; 21:593–602.
44. Henne WM, Stenmark H, Emr SD. Molecular mechanisms of the membrane sculpting ESCRT pathway. Cold Spring Harbor Perspect Biol 2013; 5:e001766. doi: 10.1101/cshperspect.a01766.
45. Henne WM, Bukovich NJ, Emr SD. The ESCRT pathway. Dev Cell 2011; 25:25–35.
46. Fujita Y, Kosaka N, Arai J, et al. Extracellular vesicles in lung microenvironment and pathogenesis. Trends Mol Med 2015; 21:593–602.
47. Ott DE. Potential roles of cellular proteins in HIV-1. Rev Med Virol 2002; 12:359–374.
48. von Schwedder UK, Stuchell M, Müller B, et al. The protein network of HIV budding. Cell 2003; 114:701–713.
49. Strack B, Calistri A, Craig S, et al. AIP1/ALIX is a binding partner for HIV-1 p6 and EIAV p6 functioning in virus budding. Cell 2003; 114:689–699.
50. Cr DP. Cellular proteins detected in HIV-1. Rev Med Virol 2008; 18:159–175.
51. Muzol F, Pineda-Molina E, Ravelli RB, et al. Structural basis for budding by the ESCRT-III factor CHMP3. Dev Cell 2006; 10:821–830.
52. Luga V, Zhang L, Vioras-Petit AM, et al. Exosomes mediate steroid mobilization of autoantibodies from the human genome. Blood 2012; 115:1542–1556.
53. de Carvalho JF, de Castro RO, da Silva EZ, et al. Neutralizes the ability of exosomes from CD4+ T cells to act as decoys during HIV-1 infection. PLoS One 2014; 9:e113691. doi: 10.1371/journal.pone.0113691.
54. Valad H, Ekstrom K, Bossios A, et al. Exosome-mediated transfer of miRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007; 9:654–659.
55. Sun L, Wang X, Zhou Y, et al. Exosomes contribute to the transmission of anti-HIV activity between TLR3-activated brain microvascular endothelial cells to macrophages. Antiviral Res 2013; 134:167–171.
56. Li J, Wang Y, Wang X, et al. Induction of immune reaction of human brain microvascular endothelial cells inhibits HIV replication in macrophages. Blood 2013; 121:2934–2942.
57. Khatua AK, Taylor HE, Hildreth JE, Popik W. Exosomes packaging APO-BEC3G confer human immunodeficiency virus resistance to recipient cells. J Virol 2009; 83:512–521.
58. Guo L, Xu XQ, Zhou L, et al. Human intestinal epithelial cells release antiviral factors that inhibit HIV infection of macrophages. Front Immunol 2019; 9:2427.
59. Welch J, Kadowd H, Schievert PM, et al. Semen exosomes promote transcriptional silencing of HIV-1 by disrupting NF-kB/Sp1/Tat circuit. J Virol 2016; 92:e00731-16. doi: 10.1128/JVI.00731-16.
60. Madison MN, Roll DR, Okeoma CM. Human semen contains exosomes with potent anti-HIV-1 activity. Retrovirology 2014; 11:102. doi: 10.1186/s12977-014-0102-0.
61. Madison MN, Jones PH, Okeoma CM. Exosomes in human semen support HIV-1 transmission by vaginal cells and block intravaginal replication of L- BM5 murine AIDS virus complex. Virolgy 2015; 482:189–201.
62. Welch J, Kadowd H, Winchester L, et al. Semen extracellular vesicles from HIV-1-infected individuals inhibit HIV-1 replication in vitro, and extracellular vesicles carry antiretroviral drugs in vivo. J Acquir Immune Defic Syndr 2020; 83:90–98.
63. Smith JA, Daniel R. Human vaginal fluid contains exosomes that have an inhibitory effect on an early step of the HIV-1 life cycle. AIDS 2016; 30:2611–2616.
83. Tang B, Li X, Ren Y, et al. MicroRNA-29a regulates lipopolysaccharide (LPS)-induced inflammatory responses in murine macrophages through the Akt1/NF-κB pathway. Exp Cell Res 2017; 360:74–80.
84. Zhang W, Petrovic JM, Callaghan D, et al. Evidence that hypoxia-inducible factor-1 (HIF-1) mediates transcriptional activation of interleukin-1beta (IL-1beta) in astrocyte cultures. J Neuroimmunol 2006; 174:63–73.
85. Duette G, Ponsya Gerber P, Rubione J, et al. Induction of HIF-1α by HIV-1 Infection in CD4(+) T cells promotes viral replication and drives extracellular vesicle-mediated inflammation. mBio 2018; 9:e00757-18.
86. Gonzalez-King H, García NA, Ontoria-Oviedo I, et al. Hypoxia inducible factor-1α potentiates jagged 1-mediated angiogenesis by mesenchymal stem cell-derived exosomes. Stem Cells 2017; 35:1747–1759.
87. Chen F, Chen J, Yang L, et al. Extracellular vesicle-packaged HIF-1α-stabilizing IncRNA from tumour-associated macrophages regulates aerobic glycolysis of breast cancer cells. Nat Cell Biol 2019; 21:498–510.
88. Saylor D, Dickens AM, Sacktor N, et al. Blood neuron-derived exosomes as biomarkers of cognitive impairment in HIV. AIDS 2017; 31:19–32.
89. Hu G, Yang L, Cai Y, et al. Emerging roles of extracellular vesicles in neurodegenerative disorders: focus on HIV-associated neurological complications. Cell Death Dis 2016; 7:e2481. doi: 10.1038/cddis.2016.336.
90. Konadu KA, Huang MB, Roth W, et al. Isolation of exosomes from the plasma of HIV-1 positive individuals. J Vis Exp 2016. doi: 10.3791/53495.
91. Karimi N, Cvjetkovic A, Jang SC, et al. Detailed analysis of the plasma extracellular vesicle proteome after separation from lipoproteins. Cell Mol Life Sci 2018; 75:2873–2886.
92. Böing AN, van der Pol E, Grootemaat AE, et al. Single-step isolation of extracellular vesicles by size-exclusion chromatography. J Extracell Vesicles 2014; 3. doi: 10.3402/jqv.v3.23430.